Skip to main content

Tempest Therapeutics, Inc 10-Q for FY2026 Q3

Tempest Therapeutics, Inc. (TPST)

10-Q 2026-11-13 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Tempest Therapeutics, Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Tempest reported $0.9 million cash as of September 30, 2026 and substantial doubt about continuing as a going concern, with cash expected to fund operations for less than 12 months. Nasdaq extended its compliance deadline to November 16, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$3.63M
compared with a net loss of $3.51M a year earlier
Diluted EPS
-$0.21
compared with -$0.79 a year earlier